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What’s	the	best	treatment		
for	CIN	2	or	3?
evidence-based answer
excision or ablation of the transformation 
zone are equally effective for treating an 
initial diagnosis of cervical intraepithelial 
neoplasia (CIN) grades 2 or 3 in women 
with a satisfactory colposcopy and no 
suggestion of microinvasive or invasive 
disease (strength of recommendation 
[sor]: a, based on randomized controlled 
trials [rCts]). 
 laser or loop electrosurgical excision 
procedure (leeP) are the preferred 
treatment methods for recurrent CIN 2  
and CIN 3 (sor: B, based on clinical trials 
without randomization). 
 For women with an unsatisfactory 
colposcopy or suspicion of invasive 
disease, a diagnostic excisional procedure 
is recommended (sor: c, based on 
consensus guidelines). 
 observation or deferred treatment may 
be acceptable for CIN 2  in adolescents 
with satisfactory colposcopy and negative 
endocervical sampling (sor: c, based on 
consensus guidelines). 
 limit diagnostic excisional procedures 
in pregnancy to cases where suspicion of 
invasive cancer is high (sor: c, based on 
consensus guidelines). 
clinical commentary
leeP provides tissue for examination
and a short recovery time
Close follow-up of observable disease and 
aggressive intervention continue to drive 
down the number of cervical cancer deaths 
each year. 
 It remains to be seen what the true 
effect of the HPv vaccine will be, although 
the presumed result will be a dramatic 
decline in high-grade lesions (CIN 2  and 
3), carcinoma in situ, and invasive disease. 
 When intervention is necessary, my 
preferred method is leeP because it 
provides tissue for examination and the 
recovery time is short. 
 Cryotherapy is an acceptable 
alternative, but the 4 to 8 weeks of 
leukorrhea and the lack of a tissue 
diagnosis often make it a less desirable 
option for patient and physician. 
Timothy Huber, MD
oroville, Calif
z		Evidence	summary
Morbidity	profile	makes		
LEEP	appear	best	
Similar efficacy. All 7 available surgical 
techniques were found to have similar ef-
ficacy,  in a 2005 Cochrane review of 28 
randomized trials.1 Resolution of CIN 
2 or 3 lesions was 77% to 98%, using 
knife cone biopsy, laser conization, loop 
excision, laser ablation, cryotherapy, or 2 
techniques not used commonly in the US, 
cold coagulation and radical diathermy. 
Surgical techniques were tested in various 
combinations, but no trial compared all 
Removal of the  
transformation 
zone, with ablative 
or excisional  
treatment, is the 
recommended 
initial treatment  
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of the techniques with one another. Most 
studies were underpowered, limiting the 
results. 
least morbidity with leeP. Morbid-
ity was compared with one-on-one tri-
als of different techniques (TabLE	 1). 
The review noted that LEEP has the least 
morbidity (such as hemorrhage, infec-
tion, cervical stenosis, and midtrimester 
pregnancy loss) while providing the most 
HPV is the  
leading cause  
of cervical cancer 
and the most 
common sexually 
transmitted 
infection in  
the US
Pap	test:	Good,	but	underused
We’ve made great progress. What was 
the 2nd leading cancer in US women in 
incidence and mortality is now 11th in  
incidence and 13th in mortality. Yet, even 
with perfect attendance at annual screen-
ings, women still get cervical cancer. And 
many still do not have screenings—they 
account for about half of all cervical can-
cers. The Pap, as good as it is, has flaws. 
The test is subjective, and sensitivity varies 
from lab to lab.9
— Dr. J. Thomas cox, university of California. 
Member, American Cancer society Cervical 
guidelines Committee, the 2002 Bethesda Workshop; 
ACs HPv vaccine Advisory Committee; author, 
AsCCP guidelines Committee
each year in the united states approxi-
mately 500,000 women are diagnosed 
with high-grade cervical cancer precursor 
lesions, CIN 2  and CIN III.4 If left un-
treated, 22% of CIN 2  lesions progress to 
carcinoma in situ or invasive cervical can-
cer, 43% regress, and 35% persist at the 
same level. Fourteen percent of untreated 
CIN 3 lesions progress, 32% regress, and 
56% persist at the same level.
HPV	vaccine:	Won't	replace		
prevention	or	protection
Although an effective vaccine is a major 
advance in the prevention of genital HPV 
and cervical cancer, it will not replace oth-
er prevention strategies, such as cervical 
cancer screening for women or protective 
sexual behaviors.Women should continue 
to get Pap tests as a safeguard against 
cervical cancer.
— Dr. anne Schuchat, Director, CDC National Center 
for Immunization and respiratory Diseases, June 
29, 2006 press release  (www.cdc.gov/od/oc/media/
pressrel/r060629.htm)
the HPv vaccine (gardasil) that prevents 
the development of lesions caused by 
HPv types 6, 11, 16, and 18, was  
approved by the us Food and Drug 
Administration in June 2006 for use in 
females 9 to 26 years oof age. shortly 
after, the Advisory Committee on Immuni-
zation Practices issued guidelines, stating 
that vaccination is recommended for all 
women <26 years of age. (www.cdc.gov/ 
vaccines/recs/schedules/adult-schedule.
htm).
HPV	testing:	adjunct	to	cytology
The United States is falling behind other 
countries in assessing how best to utilize 
HPV testing for screening. Ongoing trials 
in The Netherlands, Italy, United King-
dom, Canada, and Finland are evaluating 
whether cytology can be replaced by HPV 
DNA testing for screening. Currently, HPV 
testing is only approved as an adjunct to 
cytology for cervical cancer screening in 
the United States, and no similar trials are 
underway.10
— Dr. Thomas c. Wright, Columbia university. 
Author, 2001 Consensus guidelines on Managing 
Women with Cytological and Histological 
Abnormalities, the 2004 Interim guidance for use 
of HPv DNA testing for Primary screening, and the 
2001 Bethesda system
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reliable histology by excising tissue with-
out causing thermal artifact (fIGuRE). 
higher rate of hemorrhage with cone 
biopsy. Another systematic review of 21 
controlled trials comparing treatments 
for CIN 2 or 3 found a similar efficacy of 
all the modalities, including cone biopsy, 
cryotherapy, laser ablation, and LEEP. 
However, it also found a trend toward 
a higher rate of significant hemorrhage 
among women who received cone biop-
sies compared with women who received 
either laser ablation or LEEP.2 
Surgical	treatment	raises		
obstetric	risks
There is a concern regarding future ob-
stetric outcomes for women who have 
undergone surgical treatment of a high-
grade cervical lesion. A recent meta-
analysis of 27 controlled cohort studies 
found that cold knife conization and 
LEEP were associated with increased ob-
stetrical risks, such as delivery at less than 
37 weeks’ gestation and a birth weight 
<2500 g (TabLE	 2). Any resection that 
was more than 10 mm deep increased the 
risk of prematurity with future pregnan-
cies (pooled relative risk=2.6; 95%] CI, 
1.3–5.3).3
Recommendations	from	others
Consensus guidelines from the American 
Society for Colposcopy and Cervical Pa-
thology (ASCCP) and a practice bulletin 
from the American College of Obstetri-
For recurrent  
CIN 2 and 3,  
laser or LEEP 
are the preferred 
treatments 
CIN	2	and	3	treatment	options:	an	outcomes	comparison
comPariSon 
of TreaTmenTS ouTcome/morBiDiTy oDDS raTio (95% ci)
laser ablation vs  laser ablation had more perioperative 7.45 (1.68–33) 
cryotherapy severe bleeding
 laser ablation had higher rates of future adequate  4.64 (2.98–7.27) 
 colposcopy
laser conization vs  laser conization had higher rates of future 2.73 (1.47–5.08) 
knife conization adequate colposcopy
 laser conization had less cervical stenosis 0.39 (0.25–0.61)
laser conization vs  laser conization had more severe pain  
leeP during procedure  5.36 (1.02–17.2)
 leeP had fewer inadequate future colposcopies 0.27 (0.08–0.89)
source: Martin-Hirsch et al, Cochrane Database Syst Rev 2000.1
Table 1
figuRe
CIN	2	and	3	and	its	treatment	by	LEEP
fast track
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cians and Gynecologists (ACOG) both 
recommend immediate removal of the 
entire transformation zone, with either 
ablative or excisional treatment as initial 
treatment of CIN 2 and 3 for patients 
who are not pregnant.4,5 
Value of excisional treatment. The 
ASCCP guidelines note that there is a ben-
efit to excisional treatment, as it allows 
pathologic assessment of the excised tis-
sue. Some of the ASCCP guideline authors 
recommend excisional procedures for the 
management of large CIN 2 and 3 lesions, 
which are at increased risk of having mi-
croinvasive disease.4
For women with unsatisfactory col-
poscopy and biopsy-proven CIN 2 or 3, 
there is up to a 7% risk for an occult in-
vasive cervical carcinoma.1,4 Performing a 
diagnostic excisional procedure is recom-
mended on these patients.4,6 
ASCCP and ACOG make special rec-
ommendations for both adolescents and 
pregnant women. 
for adolescent patients with biopsy-
proven CIN 2, a recent ACOG Committee 
Opinion recommends close follow-up—
with Pap smears or colposcopies every 
4 to 6 months—due to the high rates of 
resolution of CIN 2 in adolescents.7 
for pregnant patients, diagnostic ex-
cisional procedures are associated with 
complications such as bleeding and pre-
term delivery, while there is minimal risk 
of CIN 2 or 3 progressing to invasive cer-
vical cancer.4,8 In pregnancy, follow CIN 2 
and 3 with colposcopy each trimester, and 
reevaluate at 6 to 12 weeks postpartum. 
Limit any diagnostic excisional proce-
dures to cases where you cannot rule out 
invasive cancer.4,5  n
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In pregnancy,  
follow CIN 2 or 3 
with colposcopy 
each trimester,  
and reevaluate  
at 6 to 12 weeks 
postpartum
Obstetrical	outcomes	for	CIN	2	and	3	treatment	options
TreaTmenT TyPe oBSTeTrical ouTcome relaTiVe riSk (95% ci)
cold knife conization Preterm delivery 2.59 (1.80–3.72) 
 low birth weight 2.53 (1.19–5.36) 
 Cesarean delivery 3.17 (1.07–9.40)
laser conization Preterm delivery 1.71 (0.93–3.14)
leeP Preterm delivery 1.70 (1.24–2.35) 
 low birth weight 1.82 (1.09–3.06) 
 Preterm premature rupture  2.69 (1.62–4.46) 
 of membranes
source: Kyrgiou et al, Lancet 2006.3 
Table 2
Treatment of Cin 2 and 3
